Idecabtagene vicleucel for relapsed and refractory multiple myeloma : post hoc 18-month follow-up of a phase 1 trial
© 2023. The Author(s)..
Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401) (n = 62; median follow-up, 18.1 months). The primary endpoint was safety outcomes, and secondary endpoints included overall response rate (ORR), complete response (CR) and very good partial response (VGPR). The study met its primary endpoint with low rates of grade 3/grade 4 cytokine release syndrome (6.5%) and neurotoxicity (1.6%). ORR was 75.8%; 64.5% achieved VGPR or better and 38.7% achieved CR or stringent CR. Among exploratory endpoints, median duration of response, progression-free survival (PFS) and overall survival were 10.3, 8.8 and 34.2 months, respectively, and ide-cel expansion in blood and bone marrow correlated with clinical efficacy and postinfusion reduction of soluble BCMA. Patients with PFS ≥ 18 months had more naive and less exhausted T cells in apheresis material and improved functional T cell phenotype in the drug product compared with those with less durable responses. These results confirm ide-cel safety, tolerability and efficacy and describe T cell qualities that correlate with durable response. Clinicaltrials.gov identifier : NCT02658929.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 9 vom: 17. Sept., Seite 2286-2294 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lin, Yi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8PX1X7UG4D |
|---|
| Anmerkungen: |
Date Completed 18.09.2023 Date Revised 27.09.2023 published: Print-Electronic ClinicalTrials.gov: NCT02658929 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02496-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360909809 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360909809 | ||
| 003 | DE-627 | ||
| 005 | 20231226084024.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02496-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1202.xml |
| 035 | |a (DE-627)NLM360909809 | ||
| 035 | |a (NLM)37592106 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lin, Yi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Idecabtagene vicleucel for relapsed and refractory multiple myeloma |b post hoc 18-month follow-up of a phase 1 trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.09.2023 | ||
| 500 | |a Date Revised 27.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02658929 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401) (n = 62; median follow-up, 18.1 months). The primary endpoint was safety outcomes, and secondary endpoints included overall response rate (ORR), complete response (CR) and very good partial response (VGPR). The study met its primary endpoint with low rates of grade 3/grade 4 cytokine release syndrome (6.5%) and neurotoxicity (1.6%). ORR was 75.8%; 64.5% achieved VGPR or better and 38.7% achieved CR or stringent CR. Among exploratory endpoints, median duration of response, progression-free survival (PFS) and overall survival were 10.3, 8.8 and 34.2 months, respectively, and ide-cel expansion in blood and bone marrow correlated with clinical efficacy and postinfusion reduction of soluble BCMA. Patients with PFS ≥ 18 months had more naive and less exhausted T cells in apheresis material and improved functional T cell phenotype in the drug product compared with those with less durable responses. These results confirm ide-cel safety, tolerability and efficacy and describe T cell qualities that correlate with durable response. Clinicaltrials.gov identifier : NCT02658929 | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a idecabtagene vicleucel |2 NLM | |
| 650 | 7 | |a 8PX1X7UG4D |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a B-Cell Maturation Antigen |2 NLM | |
| 700 | 1 | |a Raje, Noopur S |e verfasserin |4 aut | |
| 700 | 1 | |a Berdeja, Jesús G |e verfasserin |4 aut | |
| 700 | 1 | |a Siegel, David S |e verfasserin |4 aut | |
| 700 | 1 | |a Jagannath, Sundar |e verfasserin |4 aut | |
| 700 | 1 | |a Madduri, Deepu |e verfasserin |4 aut | |
| 700 | 1 | |a Liedtke, Michaela |e verfasserin |4 aut | |
| 700 | 1 | |a Rosenblatt, Jacalyn |e verfasserin |4 aut | |
| 700 | 1 | |a Maus, Marcela V |e verfasserin |4 aut | |
| 700 | 1 | |a Massaro, Monica |e verfasserin |4 aut | |
| 700 | 1 | |a Petrocca, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Yeri, Ashish |e verfasserin |4 aut | |
| 700 | 1 | |a Finney, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Caia, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zhihong |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Campbell, Timothy B |e verfasserin |4 aut | |
| 700 | 1 | |a Rytlewski, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Fuller, Jaymes |e verfasserin |4 aut | |
| 700 | 1 | |a Hege, Kristen |e verfasserin |4 aut | |
| 700 | 1 | |a Munshi, Nikhil C |e verfasserin |4 aut | |
| 700 | 1 | |a Kochenderfer, James N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 9 vom: 17. Sept., Seite 2286-2294 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:9 |g day:17 |g month:09 |g pages:2286-2294 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02496-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 9 |b 17 |c 09 |h 2286-2294 | ||